The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

2400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-10

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the VITdAL-ICU trial using a large oral dose of vitamin D3 in 480 adult critically ill patients, there was no benefit regarding the primary endpoint hospital length of stay. However, the predefined subgroup with severe vitamin D deficiency (25(OH)D ≤ 12ng/ml) had significantly lower 28-day mortality (36.3% placebo vs. 20.4% vitamin D group, hazard ratio (HR) 0.52 (0.30-0.89), number needed to treat = 6). Therefore, high-dose vitamin D3 in a population of severely vitamin D deficient critically ill patients is a promising and inexpensive intervention that requires confirmatory multicenter studies.

To date, only 7 interventions (e.g. noninvasive ventilation or prone positioning) have ever demonstrated mortality benefit for Intensive Care Unit (ICU) patients in multicenter trials. In case of benefit, vitamin D treatment in critically ill patients could be immediately implemented worldwide.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients

NCT01130181

Critical Illness Vitamin D Deficiency

COMPLETED PHASE3

Vitamin D to Improve Outcomes by Leveraging Early Treatment

NCT03096314

Acute Respiratory Distress Syndrome Vitamin D Deficiency Critical Illness

COMPLETED PHASE3

Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study

NCT03234218

Liver Transplant Disorder Vitamin D Deficiency

COMPLETED

Vitamin D in Ventilated ICU Patients

NCT01372995

Respiratory Failure

COMPLETED PHASE2

Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients

NCT03733418

Cognitive Decline

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A very limited number of intervention trials, most including less than 30 patients, have been published. The only phase III study, our VITdAL-ICU study recruited from 2010 to 2012 and (n=475) did not find a difference in the primary endpoint "length of hospital stay" between placebo and high-dose vitamin D3. However, there was a non-significant absolute risk reduction in all-cause hospital mortality in the total population. The difference was larger (17.5%) and significant in the predefined subgroup of patients with severe vitamin D deficiency at baseline, see Kaplan Meier curve below (n=200, 28.6 vs 46.1%, p=0.01, 0.56 (0.35-0.90) ), corresponding to a number needed to treat of 6. (51) As this was only a secondary endpoint in the predefined subgroup with severe vitamin D deficiency, this finding is hypothesis generating and requires further study, leading to this application.

In our study, we were unable to identify a mechanism by which this benefit was achieved. Interestingly, looking at the causes of death, the vitamin D group seemed to benefit in every category.

The VITDALIZE study is a pragmatic, multicenter, placebo-controlled double-blind randomized controlled phase III trial in adult critically ill patients which will be conducted in academic and non-academic centers. The sponsor is the Medical University of Graz, Austria.

Subjects will be randomised in a 1:1 ratio to receive either of the two treatments:

Vitamin D: oral/enteral pharmacological dose of cholecalciferol (vitamin D3)

* total dose 900,000
* loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT) followed by 4000 IU daily (10 drops) for the entire active study period (90 days)

Placebo: identical regime - loading dose of 37.5 ml MCT followed by 10 drops daily

This study uses a group sequential design, with one interim analysis when 50% of the planned enrolled patients in each arm (N=600 per arm) have completed their day 28 assessment by the independent data safety monitoring board. The enrollment of patients will continue while the interim analyses is performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness Vitamin D Deficiency Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days

High Dose Vitamin D3

oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000

* loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)
* followed by 4000 IU daily (10 drops) for the entire active study period (90 days)

Group Type EXPERIMENTAL

Cholecalciferol

Intervention Type DRUG

oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cholecalciferol

oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days

Intervention Type DRUG

Placebo

oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vitamin D3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years
* Anticipated ICU stay ≥ 48 hours
* Admission to ICU ≤ 72 hours before screening
* Severe vitamin D deficiency (≤12 ng/ml or undetectable)

Exclusion Criteria

* Severe gastrointestinal dysfunction (\> 400 ml residual volume)/unable to take study medication
* Do not resuscitate (DNR) order/imminent death
* hypercalcemia
* known recent nephrolithiasis, active tuberculosis or sarcoidosis
* pregnancy/lactation
* not deemed appropriate by study team/physician

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No